- Implement a proteomic platform focused on clinical applications
- Discovery of biomarkers for diagnosis, prognosis of diseases and monitor drug response
- The platform is built on state-of-the-art mass spectrometry technology
PRESENTATION
The Luxembourg clinical Proteomics, funded by a PEARL grant from Fonds National de la Recherche (FNR), aims at developing and implementing a proteomics platform focused on clinical applications.
This newly established biomarker research group within CRP-Santé is part of a wider effort in Luxembourg to develop projects that are at the forefront of biomedical research. This effort includes the Integrated BioBank of Luxembourg (IBBL), nearby hospitals and other disease researchers.
The discovery and validation of novel, reliable, protein biomarkers is crucial for the early diagnosis and prognosis of many diseases. Eventually it will benefits to the whole healthcare system.